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Abstract 
Sarcopenia refers to the loss of muscle mass and strength seen with advancing age. The 
pathophysiology is multifactorial, with loss of muscle satellite cells, changes in hormonal systems, 
chronic inflammation, oxidative stress and anabolic resistance to protein utilisation all implicated. 
Older age, female sex and immobility are important risk factors. Sarcopenia is clinically important as 
it is a major risk factor for physical frailty, falls, prolonged hospitalisation, dependency and earlier 
death. Diagnosis requires evidence of reduced muscle mass measured by handgrip strength or walk 
speed, together with evidence of low muscle mass, measured by one of a variety of techniques such 
as bioimpedance analysis or dual X-ray absorptiometry. Resistance training is the only intervention of 
proven efficacy to treat sarcopenia, but a range of nutritional and pharmacological interventions are 
under test, including myostatin inhibitors, leucine and protein supplementation, angiotensin-
converting enzyme inhibitors and allopurinol. 
  
 
What is sarcopenia? 
Sarcopenia is the loss of both muscle mass and function that occurs with advancing age. Sarcopenia, 
from the Greek meaning ‘poverty of flesh’, was first proposed in 1989 by Irwin Rosenberg as a term 
to describe the loss of muscle mass with age. The definition of sarcopenia has evolved since that time, 
to incorporate our understanding of the importance of muscle function alongside muscle mass. In 
2010 a landmark paper1 described the European Working Group on Sarcopenia in Older People 
(EWGSOP) consensus guidelines on the definition and diagnosis of sarcopenia. They provided this 
comprehensive working definition: 
 
“Sarcopenia is a syndrome characterised by progressive and generalised loss of skeletal muscle mass 
and strength with a risk of adverse outcomes such as physical disability, poor quality of life and death.” 
 
Why is sarcopenia important? 
Sarcopenia is associated with multiple adverse outcomes,2 which are of importance to older people, 
the health services they use, and the wider health economy. Sarcopenia underlies many of the 
limitations in mobility and activities of daily living that older people suffer from; it is also a key 
pathophysiology underlying physical frailty. Sarcopenia is associated with an increased risk of death, 
with one cohort study demonstrating that participants aged 80-85 with sarcopenia had double the risk 
of death during a seven year follow up compared to those without sarcopenia, after adjustment for 
multiple potential confounders.3 Sarcopenia is also an independent risk factor for falls,4 which in turn 
are a major risk factor for hip fracture, for functional decline, and for future hospitalisation. Once in 
hospital, patients with sarcopenia have longer lengths of stay than those without sarcopenia.5 
Recovery in function after discharge is also poorer for those with sarcopenia.6 
 
  
How common is sarcopenia? 
Sarcopenia is common among older populations, although the estimated prevalence varies greatly 
depending on both the population and the techniques used to diagnose the condition. A recent 
systematic review, applying the EWGSOP definition, found a prevalence of 1-29% among older 
community-dwelling adults, 14-33% among those living in long-term care settings, and 10% for those 
in acute hospital care.7 
 
What causes sarcopenia? 
The pathogenesis of sarcopenia is complex and not currently well understood. There are multiple risk 
factors involved and there are likely to be multiple pathophysiological processes contributing to its 
development.8 Alongside older age and female sex, muscle disuse caused by low levels of physical 
activity or immobility is a well-described risk factor. At the cellular level, the age-related loss of muscle 
mass that occurs in sarcopenia is caused by a decrease in the size of muscle fibres (myofibres) and in 
their total number. Both of the main types of myofibre – type 1 (slow) and type 2 (fast) – are  affected. 
Age-related oxidative damage, low-grade chronic inflammation, nutritional factors including the 
anabolic resistance of older skeletal muscle to protein nutrition, changes in hormonal systems 
including IGF-1 and the renin-angiotensin system, and mechanisms related to loss of myofibre 
innervation have all been implicated in this process. Furthermore, there is potential for each of these 
factors to contribute to loss of muscle mass versus muscle function in different ways, offering a further 
dimension of complexity. 
 
When considering aetiology, it is important to remember that sarcopenia is not the only type of 
skeletal myopathy affecting older people; for instance, those associated with chronic obstructive 
pulmonary disease and heart failure are distinct clinical entities that preferentially affect type 1 muscle 
fibres. These conditions may of course coexist with sarcopenia of age. It is also likely that within the 
accepted definition of sarcopenia there are sub-types which are yet to be characterised. There is much 
work to be done to further elicit the differences and commonalities between types and sub-types of 
skeletal myopathy and how they contribute to morbidity in older people. 
 
How can physicians diagnose sarcopenia? 
As well as providing a comprehensive working definition of sarcopenia, the EWGSOP consensus 
guidelines outlined an approach to diagnosis of sarcopenia that can be used in clinical practice. Their 
algorithm (Figure) for case-finding among older adults (age >65yrs) suggests initially identifying the 
presence of reduced gait speed, and then proceeding to test grip strength if gait speed is normal. If 
either one of these measures of muscle function suggests a deficit, the second stage in the diagnostic 
process is to measure muscle mass. The presence of both a reduction in muscle function and muscle 
mass is required to reach a diagnosis of sarcopenia. 
 
Gait speed 
Gait speed is assessed by asking the patient to walk a set distance, often 4 metres, at usual pace. Slow 
gait speed is known to be a risk factor for falls, institutionalisation and death.9 A value of <0.8m/s has 




Grip strength can be measured in the clinical setting by a device such as a Jamar dynamometer. It has 
been found to be one of the most practical methods of measuring muscle strength, and correlates 
with measures of physical performance in the lower limbs. Weak grip strength has been shown to be 
related to both incident disability and death.10,11 Cutoffs vary between populations and guidelines, but 
for European populations, cutoffs of <20Kg (females) and <30Kg (males) have been proposed by the 




There are several ways to quantify muscle mass. Computer tomography and magnetic resonance 
imaging are gold standard techniques for estimating muscle mass in research settings, but are often 
not easy to use in clinical practice. The European guidelines recommend Dual Energy X-ray 
Absorptiometry (DEXA) as the preferred low-radiation alternative for routine measurement of muscle 
mass in clinical practice. However, this method is not portable, and so may also be impractical for 
clinicians looking to diagnose sarcopenia at the point of assessment.  
 
Bioimpedance Analysis (BIA) is an inexpensive, portable and quick way to estimate body fat and lean 
muscle mass and has been validated for use in this context, with the European guidelines 
recommending it as an alternative to DEXA. Care needs to be taken to use a conversion equation that 
has been validated for both the BIA machine used and the population studied. Anthropometric 
measures, such as mid-arm circumference and skin fold thickness have previously been used to 
estimated muscle mass, but are no longer recommended as they have been validated by very few 
studies and are vulnerable to error. Similarly, although body mass index (BMI) correlates with muscle 
mass, it is not sufficiently precise to allow diagnosis of low muscle mass, and does not allow diagnosis 
of sarcopenic obesity – the combination of high body fat with low muscle mass. 
 
What treatments are available for sarcopenia? 
Exercise 
Resistance exercise remains the intervention with the most supporting evidence for effectiveness in 
the management of sarcopenia, and so is the current treatment of choice. Meta-analyses have shown 
improvements in physical performance and muscle strength with resistance exercise in the context of 
sarcopenia.7. Outcomes vary between exercise studies, as does the nature of the exercise programme 
offered. This has led to difficulties in translating research findings in to practice, and the focus now 
needs to be on producing resistance exercise programmes that are deliverable at scale within 
communities and across health services. 
 
Diet 
For those unable or unwilling to undertake resistance exercise, the management options are more 
limited, with the majority remaining in the experimental phase. Dietary modification and 
supplementation are areas of intense research activity, with interest in boosting protein; the impact 
of vitamin D supplementation, and the effect of anti-oxidants and creatine. Supplementing bulk 
protein intake may be difficult for older people, and evidence for effectiveness in sarcopenia is limited. 
Supplementation with leucine or its metabolites may offer a more effective alternative however, and 
large scale trials are currently underway. Vitamin D supplementation has a small benefit on muscle 
strength but not muscle mass,12 and creatine may augment the effect of resistance training, at least 
on muscle mass.13,14 The effects of supplementation in patients with sarcopenia as opposed to healthy 
older people require further study however. 
 
Medication  
There is significant potential for drug development in the area of sarcopenia research, although 
currently there is no recommended pharmacological treatment. Encouraging recent trial data 
suggests that inhibitors of the myostatin system may have a role in treating sarcopenia,15 but phase 
III trials are awaited. Recent data from the TTT trials of testosterone did not show a useful 
improvement in physical function,16 but large trials have not been conducted specifically in patients 
with sarcopenia. Other trials are examining the use of angiotensin-converting enzyme inhibitors, and 
also allopurinol as an antioxidant.  
 
Conclusion 
Sarcopenia is associated with multiple adverse outcomes, including frailty, disability, morbidity and 
mortality. It is an exciting, emerging area of geriatric medicine, highly relevant to the problems of 
functional impairment and dependency that affect large numbers of our ageing population. Recent 
efforts to achieve international consensus on the definition and diagnosis of sarcopenia have 
accelerated progress in sarcopenia research, and there are growing efforts within the specialty of 
geriatric medicine to translate research findings in to clinical practice. For the frontline physician, 
techniques to measure muscle mass and function will ultimately add to the existing tools used the 
assessment of older people presenting to hospital. Furthermore, our understanding of sarcopenia 
using a life course approach could significantly broaden the opportunities to modify factors 
contributing to its development prior to old age, thus offering a way to improve the health and 




• Sarcopenia is the loss of both muscle mass and function that occurs with advancing age. It is 
associated with multiple adverse outcomes, including frailty, disability and death. 
• Older age, female sex, and muscle disuse are known risk factors, although the underlying 
pathogenesis is complex and not currently well understood. 
• Sarcopenia is diagnosed by demonstrating the presence of both a reduction in muscle function 
and muscle mass. In clinical practice this can be achieved by combining measures of gait speed 
and hand grip strength with bioimpedance analysis. 
• Sarcopenia can be effectively treated using resistance exercise, and there is now a developing 
focus on how best to deliver this treatment across health services. 
• Treatments for sarcopenia are the subject of intensive research activity. The impact of dietary 
modification, and the role of new and existing drugs are all areas of active investigation. 
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Self-Assessment Questions 
Best of 5 format 
 
1. Regarding the treatment of sarcopenia, which of the following statements is true? 
a. Non-specific antioxidants have a role in reversing the loss of muscle mass and 
function in sarcopenia 
b. Older people with proven sarcopenia should increase daily protein intake to at 
least 1.5g/kg/day 
c. Progressive resistance exercise training (PRT) has been shown to be effective in 
improving both muscle strength and physical performance 
d. Testosterone is a safe and effective drug therapy for sarcopenia 
e. Vitamin D supplementation increases muscle mass, making this a potential 
alternative treatment for those who are unable to exercise 
 
Answer C is true – there is evidence that PRT improves muscle strength and physical performance, 
and this is the treatment of choice in sarcopenia. 
A – there are few studies on the use of antioxidants to improve muscle strength – although this 
remains a promising area for future research 
B – while theoretically an increased protein dietary protein intake should be helpful in the 
management of sarcopenia, there is not yet the evidence to recommend this approach. 
D – there are concerns over the cardiovascular side effects associated with testosterone  
E – Vitamin D may be a potential alternative treatment for sarcopenia through improving muscle 
function, but it has not been shown to increase muscle mass 
 
 
2. Regarding the pathogenesis of sarcopenia: 
a. Accumulation of reactive oxygen species and subsequent damage are factors 
implicated in the loss of muscle mass and strength. 
b. Hormonal changes associated with the development of sarcopenia are well 
understood 
c. Myopathies associated with chronic lung disease and heart failure are indistinct from 
sarcopenia of age. 
d. Rodent models of skeletal ageing are applicable to humans as the ratio of slow to fast 
myofibres is similar 
e. Only Type 2 (fast) myofibres are affected 
 
Answer A is true – accumulation of reactive oxygen species is likely to be a key mechanism in the 
pathogenesis of sarcopenia 
B – there are numerous hormonal changes implicated, but how these interact to contribute to the 
development of sarcopenia is not well understood 
C- myopathies associated with COPD and heart failure are distinct clinical entities 
D – Rodent models of skeletal ageing have been used to research the pathogenesis of sarcopenia, 
but translating finds across to humans must be approached cautiously as rodent muscle is 
predominantly made up of fast myofibres in contrast to human muscle which is predominantly slow. 
E – both type 1 (slow) and type 2 (fast) myofibres are affected in sarcopenia 
 
 
Which of the following procedures would be best suited to diagnosing sarcopenia in clinical 
practice? 
a) Measurement of grip strength and walk speed 
b) Measurement of grip strength, walk speed and mid-arm muscle circumference 
c) Measurement of thigh muscle cross-sectional area using computed tomography 
d) Measurement of grip strength, walk speed and muscle mass using dual X-ray absorptiometry 
e) Measurement of grip strength, walk speed and fat mass using bioimpedance analysis 
 
Answers: 
A and C – both muscle mass and muscle function need to be measured to make a diagnosis of 
sarcopenia 
B – Mid-arm muscle circumference does not give a sufficiently accurate measure of muscle mass and 
its use is not recommended for making the diagnosis of sarcopenia 
D – is correct. DEXA is more accurate than bioimpedance, although less practical in clinical settings 
E – Bioimpedance can be used to measure muscle mass, but measuring fat mass does not form part 
of the diagnostic criteria for sarcopenia. 
Figure. Algorithm for diagnosing sarcopenia (reproduced with permission from [1]) 
 
 

